Key Points
- Elizabeth Reed sold 10,000 shares of Travere Therapeutics (NASDAQ:TVTX) on March 16 at an average price of $28.09, receiving $280,900 and reducing her holding by 8.68% to 105,211 shares valued at about $2.96 million.
- TVTX opened at $26.96, has a market cap of $2.49 billion, a negative P/E (-89.86), a 52‑week range of $12.91–$42.13, and 50/200‑day moving averages near $29.61 and $30.31 respectively.
- Analysts' consensus is a Moderate Buy with an average price target of $38.17, based on 10 Buys, 3 Holds and 1 Sell and recent price targets ranging up to the high $40s from some firms.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 10,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.09, for a total value of $280,900.00. Following the completion of the transaction, the insider directly owned 105,211 shares in the company, valued at $2,955,376.99. This trade represents a 8.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Travere Therapeutics Price Performance
TVTX stock opened at $26.96 on Thursday. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -89.86 and a beta of 0.81. Travere Therapeutics, Inc. has a fifty-two week low of $12.91 and a fifty-two week high of $42.13. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The business has a 50 day moving average price of $29.61 and a 200 day moving average price of $30.31.
Hedge Funds Weigh In On Travere Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company's stock valued at $1,029,000 after buying an additional 6,831 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Travere Therapeutics in the 2nd quarter valued at $241,000. Geode Capital Management LLC lifted its stake in shares of Travere Therapeutics by 1.4% during the second quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company's stock worth $29,658,000 after purchasing an additional 27,040 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Travere Therapeutics by 9.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 19,764 shares of the company's stock worth $293,000 after buying an additional 1,661 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Travere Therapeutics in the second quarter valued at about $473,000.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a report on Friday, November 28th. Guggenheim reissued a "buy" rating and set a $49.00 target price on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen downgraded Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 21st. Finally, Piper Sandler increased their price target on shares of Travere Therapeutics from $35.00 to $38.00 and gave the company a "neutral" rating in a research report on Friday, February 6th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.17.
Check Out Our Latest Analysis on TVTX
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
